The Lancet Publishes Two Phase 3 Studies Showing CholesterolLowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol

THOUSAND OAKS Calif. Oct. 1 2014 PRNewswire &160;Amgen NASDAQAMGN today announced The Lancet published data from two Phase 3 studies RUTHERFORD2 and TESLA that showed treatment with evolocumab a novel investigational lowdensity lipoprotein cholesterol ...